Investor Presentaiton
For personal use only
Company overview
An established global leader in radiopharmaceuticals
Extensive portfolio of diagnostic and
therapeutic assets with compelling
clinical data
12,150 patient doses in past 12 months1
FDA approval for TLX591-CDx (Illuccix®)2
18 active clinical studies (8 indications)³
Leading supply chain and
distribution network
80 countries in the Telix distribution network
countries with a manufacturing footprint
INDIANAPOLIS
United States
Regional Office
LIEGE and
BRUSSELS
(Seneffe)
Belgium
Regional Office
GENEVA
Switzerland
MELBOURNE
Australia
Corporate Head Office
Commercial
Hub
TELIX
PHARMACEUTICALS
KYOTO
Japan
Regional Office
1. Clinical trial doses and magisterial / compassionate use of TLX591-CDx. 12 months from Q4 2020
2. U.S. Food and Drug Administration - ASX 20/12/21
Telix Pharmaceuticals Limited (ASX: TLX)
3. Includes partnered investigator-led studies.
14View entire presentation